Joris L. Vos

Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma

Joris L. Vos, Joris B.W. Elbers, Oscar Krijgsman et al. · Nature Communications · 2021 · 336 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

A pan-cancer analysis of the microbiome in metastatic cancer

Thomas Battaglia, Iris Mimpen, Joleen J.H. Traets et al. · Cell · 2024 · 193 citations · Full text

Life Sciences, Microbiology, Oncology +17

Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data

Seong‐Keun Yoo, Conall Fitzgerald, Byuri Angela Cho et al. · Nature Medicine · 2025 · 109 citations · Full text

Medicine, Immunology, Oncology +17

CD4+ T cells produce IFN-I to license cDC1s for induction of cytotoxic T-cell activity in human tumors

Xin Lei, Daniël C. de Groot, Marij J.P. Welters et al. · Cellular and Molecular Immunology · 2024 · 58 citations · Full text

Life Sciences, Immunology, Oncology +16

Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial

Joris L. Vos, Bharat Burman, Swati Jain et al. · Nature Medicine · 2023 · 55 citations · Full text

Medicine, Oncology, Pharmacotherapy +9